FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111710483> ?p ?o ?g. }

• W2111710483 endingPage "1109" @default.
• W2111710483 startingPage "1103" @default.
• W2111710483 abstract "Purpose Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, induces radiographic regressions and symptomatic improvement in patients with non–small-cell lung cancer (NSCLC). Phase II trials suggested female sex and adenocarcinoma were associated with response. We undertook this analysis to identify additional clinical and pathologic features associated with sensitivity to gefitinib. Patients and Methods We reviewed medical records, pathologic material, and imaging studies of all 139 NSCLC patients treated on one of three consecutive studies of gefitinib monotherapy performed at our institution. We identified patients experiencing a major objective response and compared their clinical and pathologic features with the others. Univariate and multivariable analyses were performed on potential predictive features associated with sensitivity to gefitinib. Results Of 139 patients, 21 (15%; 95% CI, 9% to 21%), experienced a partial radiographic response. Variables identified as significant in univariate analysis included adenocarcinoma versus other NSCLC (19% v 0%; P = .004), adenocarcinoma with bronchioloalveolar features versus other adenocarcinomas (38% v 14%; P < .001), never smoker status versus former/current (36% v 8%; P < .001), and Karnofsky performance status ≥ 80% versus ≤ 70% (22% v 8%; P = .03). Multivariable analysis revealed the presence of adenocarcinoma with any bronchioloalveolar features (P = .004) and being a never smoker (P = .006) were independent predictors of response. Conclusion Our data suggest that individuals in whom gefitinib is efficacious are more likely to have adenocarcinomas of the bronchioloalveolar subtype and to be never smokers. These observations may provide clues to mechanisms determining sensitivity to this agent and suggest that NSCLC has a different biology in patients who never smoked and those with bronchioloalveolar carcinoma." @default.
• W2111710483 created "2016-06-24" @default.
• W2111710483 creator A5003980612 @default.
• W2111710483 creator A5011548134 @default.
• W2111710483 creator A5012122212 @default.
• W2111710483 creator A5033948459 @default.
• W2111710483 creator A5035120516 @default.
• W2111710483 creator A5035446911 @default.
• W2111710483 creator A5039791495 @default.
• W2111710483 creator A5049024746 @default.
• W2111710483 creator A5050489521 @default.
• W2111710483 creator A5052336062 @default.
• W2111710483 creator A5054116903 @default.
• W2111710483 creator A5060929583 @default.
• W2111710483 creator A5062616992 @default.
• W2111710483 creator A5064587869 @default.
• W2111710483 creator A5075877134 @default.
• W2111710483 creator A5077103441 @default.
• W2111710483 creator A5078867875 @default.
• W2111710483 date "2004-03-15" @default.
• W2111710483 modified "2023-10-10" @default.
• W2111710483 title "Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer" @default.
• W2111710483 cites W1803099259 @default.
• W2111710483 cites W1839238860 @default.
• W2111710483 cites W1966738726 @default.
• W2111710483 cites W1995634658 @default.
• W2111710483 cites W1999076809 @default.
• W2111710483 cites W2010836341 @default.
• W2111710483 cites W2108947370 @default.
• W2111710483 cites W2119363473 @default.
• W2111710483 cites W2120718661 @default.
• W2111710483 cites W2126314379 @default.
• W2111710483 cites W2127445851 @default.
• W2111710483 cites W2130652363 @default.
• W2111710483 cites W2140626630 @default.
• W2111710483 cites W2142661339 @default.
• W2111710483 cites W2144932698 @default.
• W2111710483 cites W2146404049 @default.
• W2111710483 cites W2167368130 @default.
• W2111710483 cites W2318605753 @default.
• W2111710483 cites W2414051637 @default.
• W2111710483 cites W4239330499 @default.
• W2111710483 cites W4254458241 @default.
• W2111710483 doi "https://doi.org/10.1200/jco.2004.08.158" @default.
• W2111710483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15020612" @default.
• W2111710483 hasPublicationYear "2004" @default.
• W2111710483 type Work @default.
• W2111710483 sameAs 2111710483 @default.
• W2111710483 citedByCount "700" @default.
• W2111710483 countsByYear W21117104832012 @default.
• W2111710483 countsByYear W21117104832013 @default.
• W2111710483 countsByYear W21117104832014 @default.
• W2111710483 countsByYear W21117104832015 @default.
• W2111710483 countsByYear W21117104832016 @default.
• W2111710483 countsByYear W21117104832017 @default.
• W2111710483 countsByYear W21117104832018 @default.
• W2111710483 countsByYear W21117104832019 @default.
• W2111710483 countsByYear W21117104832020 @default.
• W2111710483 countsByYear W21117104832021 @default.
• W2111710483 countsByYear W21117104832022 @default.
• W2111710483 countsByYear W21117104832023 @default.
• W2111710483 crossrefType "journal-article" @default.
• W2111710483 hasAuthorship W2111710483A5003980612 @default.
• W2111710483 hasAuthorship W2111710483A5011548134 @default.
• W2111710483 hasAuthorship W2111710483A5012122212 @default.
• W2111710483 hasAuthorship W2111710483A5033948459 @default.
• W2111710483 hasAuthorship W2111710483A5035120516 @default.
• W2111710483 hasAuthorship W2111710483A5035446911 @default.
• W2111710483 hasAuthorship W2111710483A5039791495 @default.
• W2111710483 hasAuthorship W2111710483A5049024746 @default.
• W2111710483 hasAuthorship W2111710483A5050489521 @default.
• W2111710483 hasAuthorship W2111710483A5052336062 @default.
• W2111710483 hasAuthorship W2111710483A5054116903 @default.
• W2111710483 hasAuthorship W2111710483A5060929583 @default.
• W2111710483 hasAuthorship W2111710483A5062616992 @default.
• W2111710483 hasAuthorship W2111710483A5064587869 @default.
• W2111710483 hasAuthorship W2111710483A5075877134 @default.
• W2111710483 hasAuthorship W2111710483A5077103441 @default.
• W2111710483 hasAuthorship W2111710483A5078867875 @default.
• W2111710483 hasBestOaLocation W21117104831 @default.
• W2111710483 hasConcept C121608353 @default.
• W2111710483 hasConcept C126322002 @default.
• W2111710483 hasConcept C143998085 @default.
• W2111710483 hasConcept C144301174 @default.
• W2111710483 hasConcept C2776256026 @default.
• W2111710483 hasConcept C2778820342 @default.
• W2111710483 hasConcept C2779438470 @default.
• W2111710483 hasConcept C2780580887 @default.
• W2111710483 hasConcept C2781182431 @default.
• W2111710483 hasConcept C38180746 @default.
• W2111710483 hasConcept C535046627 @default.
• W2111710483 hasConcept C71924100 @default.
• W2111710483 hasConcept C90924648 @default.
• W2111710483 hasConceptScore W2111710483C121608353 @default.
• W2111710483 hasConceptScore W2111710483C126322002 @default.
• W2111710483 hasConceptScore W2111710483C143998085 @default.
• W2111710483 hasConceptScore W2111710483C144301174 @default.
• W2111710483 hasConceptScore W2111710483C2776256026 @default.

• next